Erlotinib

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
26034
Randomized phase II of TARCEVA TM (Erlotinib) versus Temozolomide or BCNU in patients with recurrent glioblastoma multiforme.
55041
A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer

Back to Protocol section